Cannabis
IM Cannabis Reports Second Quarter Financial Results
IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023
TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ — IM Cannabis Corp. (the “Company” or “IMC“) (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated.
Q2 2024 Financial Highlights
- 12% Revenue increase to $14.8M vs. $13.2M in Q2 2023
- 129% increase in IMC Germany sales vs. Q2 2023 to $3.5M. IMC Germany sales now make up 24% of the entire Company revenue, a growth of +105% vs Q2 2023
- 78% decrease in GM vs. 26% in Q2 2023 to 6% mainly caused by inventory clearance of $0.8M plus an accrual of $1.1M for slow moving stock
- 29% decrease in operating expenses to $3.7M vs. $5.2M in Q2 2023
Management Commentary
“The German market is not just poised to start delivering significant growth after the April 1st cannabis legalization, we can already see the impact the legalization has had on our German business. We were well positioned to take advantage of the growing market and delivered a 200% increase in sales in Q2,” said Oren Shuster, Chief Executive Officer of IMC. “We are actively making sure that we are allotting the resources and support the German business needs to deliver further accelerated growth.”
“Our revenue in Q2 increased by 12 vs Q2 2023. This growth was driven in part by the 200% Germany grew in Q2 vs Q1 2024. Our selling price per gram of dried flower also increased 21% vs Q2 2023 to $6.09 per gram. In addition, our operating expenses continued to decrease by 29% vs Q2 2023, as a result of last year’s restructuring,” commented Uri Birenberg, Chief Financial Officer of IMC. “Conversely, we cleared old raw material and accrued for slow moving stock for total of about $1.9 million which impacted our cost of sales, gross margin, and gross profit.”
Q2 2024 Conference Call
The Company will host a Zoom web conference call today at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
Q2 2024 Financial Results
- Revenues for the second quarter of 2024 were $14.8 million compared to $13.2 million in Q2 2023, an increase of $1.6 million or 11.7%. The increase is mainly attributed to accelerated growth in Germany revenue of $2 million net and decreased net Revenue in Israel of $0.4 million, which consists of Oranim deal cancellation effect in decreased Revenue of $2.4 million.
- Total Dried Flower sold in Q2 2024 was approximately 2,333 kg with an average selling price of $6.09 per gram, compared to approximately 2,128kg in Q2 2023, with an average selling price of $5.04 per gram, which is an increase of 21%.
- Cost of revenues for Q2 2024 were $13.9 million compared to $9.5 million in Q2 2023, an increase of $4.4 million or 46.6%, mainly due to an increase in Company revenue related costs of approximately $2.5 million, clearing of old raw materials of approximately $0.8 million and accrued for slow inventory of approximately $1.1 million.
- Gross profit for the second quarter of 2024 was $0.8 million, compared to $3.5 million in Q2 2023, a decrease of 75.6%. The downside is attributed mainly to the clearing of old inventory, accrual for slow moving inventory of approximately $1.9 million and slow-moving stock that was moved out at a lower price. Company fair value adjustment was $0 and $0.3 million for the Q2 2024 and Q2 2023 respectively.
- G&A Expenses in Q2 2024 were $2.2 million, compared to $2.4 million in Q2 2023, a decrease of $0.2 million or 9.5%. The decrease in the G&A expense is attributable mainly to insurance of approximately $0.2 million.
- Selling and Marketing Expenses in Q2 2024 were $1.5 million, compared to $2.6 million in Q2 2023, a decrease of $1.1 million or 44% mainly due to the revocation of Oranim agreement of $0.6 million and decrease in salaries and professional services of $0.4 million.
- Total operating expenses in Q2 2024 were $3.7 million compared to $5.2 million in Q2 2023, a decrease of $1.5 million or of 29% mainly due to decrease in salaries of approximately $0.4 million, insurance of $0.2 million, depreciation expenses of $0.3 million and professional services of $0.2 million.
- Net Loss in Q2 2024 was $3.5 million, compared to $3.7 million in Q2 2023.
- Basic and diluted Loss per Share in Q2 2024 was $0.23, compared to a loss of $0.26 per Share in Q2 2023.
- Non-IFRS Adjusted EBITDA loss in Q2 2024 was $2.3 million, compared to an Adjusted EBITDA loss of $0.5 million in Q2 2023 a loss increase of 357%.
- Cash and Cash Equivalents as of June 30, 2024, were $0.7 million compared to $1.8 million on December 31, 2023.
- Total assets as of June 30, 2024, were $40.2 million, compared to $48.8 million on December 31, 2023, a decrease of $8.6 million or 17.6%.
The decrease is mainly attributed to the Oranim agreement cancelation of $9.5 million of which mainly attributed to; goodwill $3.5 million, intangible asset $1.4 million, inventory $0.8 million, trade receivables $1.3 million and property plant and equipment $0.8 million and reduction of cash and cash equivalents of $0.3 million.
In addition to the Oranim revocation agreement effect, there is a total asset increase of $0.9 million mainly due to an increase of $5.8 million in trade receivables offset by $3.4 million reduction in Inventory, reduction of Cash and cash equivalents of $0.8 million and reduction of $0.7 million in intangible assets.
- Total Liabilities as of June 30, 2024, were $34.7 million, compared to $35.1 million on December 31, 2023, a decrease of $0.4 million or 1.1%.
The decrease was mainly due to the Oranim agreement cancelation of $6.8 million of which mainly attributed to a decrease in PUT option liability in the amount of $2.0 million, a decrease in purchase consideration payable in the amount of $2.2 million, a decrease of $1.6 million in trade payables, a decrease of $0.4 million in lease liabilities and a decrease of $0.3 million in deferred tax liability.
In addition to the Oranim revocation agreement effect, there is a total liabilities increase of $6.4 million mainly due to an increase of $6.2 million in trade payables offset by a $1.7 million reduction in other accounts payable.
The Company’s financial statements as of June 30, 2024, includes a note regarding the Company’s ability to continue as a going concern. The Company’s Q2 2024 financial results do not include any adjustments relating to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. For more information, please refer to the “Liquidity and Capital Resources” and “Risk Factors” sections in the Company’s management’s discussion and analysis for the quarter ended June 30, 2024.
Non-IFRS Measures
This press release makes reference to “Gross Margin” and “Adjusted EBITDA”, which are financial measures that are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as complementary information to the Company’s IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should neither be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.
For an explanation of how management defines Gross Margin and Adjusted EBITDA, see the Company’s management’s discussion and analysis for the period ended June 30, 2024, available under the Company’s SEDAR+ profile at www.sedarplus.ca on EDGAR at www.sec.gov/edgar.
We reconcile these non-IFRS financial measures to the most comparable IFRS measures as set out below.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the impact of the Israel-Hamas war on the Company, including its operations and the medical cannabis industry in Israel; the timing and impact of the legalization of medicinal cannabis in Germany, including, the Company having it “all in house”; the Company being positioned to take advantage of the legalization; the Company’s growth in 2024; the market growth for medicinal cannabis in Germany; the stated benefits of the Company’s EU-GMP processing facility and an EU-GDP logistics center; the Company to host a teleconference meeting as stated; and the Company’s stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to focus and resources to achieve sustainable and profitable growth in its highest value markets; the Company’s ability to mitigate the impact of the Israel-Hamas war on the Company; the Company’s ability to take advantage of the legalization of medicinal cannabis in Germany; the Company’s ability to host a teleconference meeting as stated; and the Company’s ability to carry out its stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to host a teleconference meeting as stated.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||||
|
Canadian Dollars in thousands |
||||||
|
June 30, 2024 |
December 31, 2023 |
|||||
|
Note |
(Unaudited) |
(Audited) |
||||
|
ASSETS |
||||||
|
CURRENT ASSETS: |
||||||
|
Cash and cash equivalents |
$ 700 |
$ 1,813 |
||||
|
Trade receivables |
12,087 |
7,651 |
||||
|
Advances to suppliers |
788 |
936 |
||||
|
Other accounts receivable |
3,648 |
3,889 |
||||
|
Inventories |
3 |
5,719 |
9,976 |
|||
|
22,942 |
24,265 |
|||||
|
NON-CURRENT ASSETS: |
||||||
|
Property, plant and equipment, net |
4,052 |
5,058 |
||||
|
Investments in affiliates |
2,284 |
2,285 |
||||
|
Right-of-use assets, net |
626 |
1,307 |
||||
|
Intangible assets, net |
3,678 |
5,803 |
||||
|
Goodwill |
6,634 |
10,095 |
||||
|
17,274 |
24,548 |
|||||
|
Total assets |
$ 40,216 |
$ 48,813 |
||||
|
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
||||||
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||||
|
Canadian Dollars in thousands |
||||||
|
June 30, 2024 |
December 31, 2023 |
|||||
|
Note |
(Unaudited) |
(Audited) |
||||
|
LIABILITIES AND EQUITY |
||||||
|
CURRENT LIABILITIES:
|
||||||
|
Trade payables |
$ 13,877 |
$ 9,223 |
||||
|
Bank loans and credit facilities |
12,746 |
12,119 |
||||
|
Other accounts payable and accrued expenses |
4,486 |
6,218 |
||||
|
Accrued purchase consideration liabilities |
– |
2,097 |
||||
|
PUT Option liability |
– |
2,697 |
||||
|
Convertible debt |
2,002 |
– |
||||
|
Current maturities of operating lease liabilities |
292 |
454 |
||||
|
33,403 |
32,808 |
|||||
|
NON-CURRENT LIABILITIES:
|
||||||
|
Warrants measured at fair value |
4 |
57 |
38 |
|||
|
Operating lease liabilities |
301 |
815 |
||||
|
Long-term loans |
401 |
394 |
||||
|
Employee benefit liabilities, net |
47 |
95 |
||||
|
Deferred tax liability, net |
526 |
963 |
||||
|
1,332 |
2,305 |
|||||
|
Total liabilities |
34,735 |
35,113 |
||||
|
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: |
5 |
|||||
|
Share capital and premium |
253,966 |
253,882 |
||||
|
Translation reserve |
1,579 |
95 |
||||
|
Reserve from share-based payment transactions |
9,673 |
9,637 |
||||
|
Conversion option for convertible debt |
327 |
– |
||||
|
Accumulated deficit |
(258,478) |
(249,145) |
||||
|
Total equity attributable to equity holders of the Company |
7,067 |
14,469 |
||||
|
Non-controlling interests |
(1,586) |
(769) |
||||
|
Total equity |
5,481 |
13,700 |
||||
|
Total liabilities and equity |
$ 40,216 |
$ 48,813 |
||||
|
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
||||||
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS |
||||||||
|
AND OTHER COMPREHENSIVE INCOME (UNAUDITED) |
||||||||
|
Canadian Dollars in thousands, except per share data |
||||||||
|
Six months ended June 30, |
Three months ended June 30, |
|||||||
|
2024 |
2023 |
2024 |
2023 |
|||||
|
(Unaudited) |
||||||||
|
Revenues |
$ 26,813 |
$ 25,736 |
$ 14,750 |
$ 13,207 |
||||
|
Cost of revenues |
24,165 |
18,759 |
13,891 |
9,473 |
||||
|
Gross profit before fair value adjustments |
2,648 |
6,977 |
859 |
3,734 |
||||
|
Fair value adjustments: |
||||||||
|
Realized fair value adjustments on inventory sold in the period |
(25) |
(617) |
(15) |
(278) |
||||
|
Total fair value adjustments |
(25) |
(617) |
(15) |
(278) |
||||
|
Gross profit |
2,623 |
6,360 |
844 |
3,456 |
||||
|
General and administrative expenses |
4,495 |
5,563 |
2,163 |
2,389 |
||||
|
Selling and marketing expenses |
3,773 |
5,427 |
1,481 |
2,622 |
||||
|
Restructuring expenses |
– |
617 |
– |
334 |
||||
|
Share-based compensation |
120 |
121 |
88 |
(137) |
||||
|
Loss on deconsolidation |
2,734 |
– |
(19) |
– |
||||
|
Total operating expenses |
11,122 |
11,728 |
3,713 |
5,208 |
||||
|
Operating loss |
8,499 |
5,368 |
2,869 |
1,752 |
||||
|
Finance income (expenses), net |
(1,927) |
621 |
(1,426) |
(2,114) |
||||
|
Loss before income taxes |
(10,426) |
(4,747) |
(4,295) |
(3,866) |
||||
|
Income tax benefit |
(950) |
(175) |
(839) |
(160) |
||||
|
Net loss |
(9,476) |
(4,572) |
(3,456) |
(3,706) |
||||
|
Other comprehensive income (loss) that will not be reclassified |
||||||||
|
Remeasurement gain on defined benefit plan |
67 |
36 |
– |
– |
||||
|
Exchange differences on translation to presentation currency |
1,517 |
(661) |
187 |
(99) |
||||
|
Total other comprehensive income that will not be reclassified to |
1,584 |
(625) |
187 |
(99) |
||||
|
Other comprehensive income (loss) that will be reclassified to |
||||||||
|
Adjustments arising from translating financial statements of |
(26) |
466 |
9 |
311 |
||||
|
Total other comprehensive income (loss) that will be reclassified |
(26) |
466 |
9 |
311 |
||||
|
Total other comprehensive income (loss) |
1,558 |
(159) |
196 |
212 |
||||
|
Total comprehensive loss |
$ (7,918) |
$ (4,731) |
$ (3,260) |
$ (3,494) |
||||
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS |
|||||||||||
|
AND OTHER COMPREHENSIVE INCOME (UNAUDITED) |
|||||||||||
|
Canadian Dollars in thousands, except per share data |
|||||||||||
|
Six months ended June 30, |
Three months ended June 30, |
||||||||||
|
2024 |
2023 |
2024 |
2023 |
||||||||
|
Note |
(Unaudited) |
||||||||||
|
Net loss attributable to: |
|||||||||||
|
Equity holders of the Company |
$ (8,652) |
$ (4,059) |
$ (3,029) |
$ (3,459) |
|||||||
|
Non-controlling interests |
(824) |
(513) |
(427) |
(247) |
|||||||
|
$ (9,476) |
$ (4,572) |
$ (3,456) |
$ (3,706) |
||||||||
|
Total comprehensive loss attributable to: |
|||||||||||
|
Equity holders of the Company |
$ (7,101) |
$ (4,209) |
$ (2,840) |
$ (3,250) |
|||||||
|
Non-controlling interests |
(817) |
(522) |
(420) |
(244) |
|||||||
|
$ (7,918) |
$ (4,731) |
$ (3,260) |
$ (3,494) |
||||||||
|
Net income (loss) per share attributable to equity holders of the Company:
|
6 |
||||||||||
|
Basic loss per share (in CAD) |
$ (0.65) |
$ (0.33) |
$ (0.23) |
$ (0.26) |
|||||||
|
Diluted loss per share (in CAD) |
$ (0.65) |
$ (0.33) |
$ (0.23) |
$ (0.26) |
|||||||
|
Earnings (loss) per share attributable to equity holders of the Company:
|
|||||||||||
|
Basic loss per share (in CAD) |
$ (0.65) |
$ (0.33) |
$ (0.23) |
$ (0.26) |
|||||||
|
Diluted loss per share (in CAD) |
$ (0.65) |
$ (0.33) |
$ (0.23) |
$ (0.26) |
|||||||
|
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
|||||||||||
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) |
||||||||||||||||
|
Canadian Dollars in thousands |
||||||||||||||||
|
Share |
Reserve from |
Conversion |
Translation |
Accumulated |
Total |
Non- |
Total |
|||||||||
|
Balance as of January 1, 2024 |
$ 253,882 |
$ 9,637 |
$ – |
$ 95 |
$ (249,145) |
$ 14,469 |
$ (769) |
$ 13,700 |
||||||||
|
Net loss |
– |
– |
– |
– |
(8,652) |
(8,652) |
(824) |
(9,476) |
||||||||
|
Total other comprehensive loss |
– |
– |
– |
1,484 |
67 |
1,551 |
7 |
1,558 |
||||||||
|
Total comprehensive loss |
– |
– |
– |
1,484 |
(8,585) |
(7,101) |
(817) |
(7,918) |
||||||||
|
Net proceeds of convertible debt allocated to conversion option |
– |
– |
327 |
– |
– |
327 |
– |
327 |
||||||||
|
Other comprehensive income Classification |
– |
– |
– |
– |
(748) |
(748) |
– |
(748) |
||||||||
|
Share-based compensation |
– |
120 |
– |
– |
– |
120 |
– |
120 |
||||||||
|
Forfeited options |
84 |
(84) |
– |
– |
– |
– |
– |
– |
||||||||
|
Balance as of June 30, 2024 |
$ 253,966 |
$ 9,673 |
$ 327 |
$ 1,579 |
$ (258,478) |
$ 7,067 |
$ (1,586) |
$ 5,481 |
||||||||
|
Share |
Reserve from |
Translation |
Accumulated |
Total |
Non- |
Total |
||||||||
|
Balance as of January 1, 2023 |
$ 245,776 |
$ 15,167 |
$ 1,283 |
$ (239,574) |
$ 22,652 |
$ 1,145 |
$ 23,797 |
|||||||
|
Net loss |
– |
– |
– |
(4,059) |
(4,059) |
(513) |
(4,572) |
|||||||
|
Total other comprehensive loss |
– |
– |
(186) |
36 |
(150) |
(9) |
(159) |
|||||||
|
Total comprehensive loss |
– |
– |
(186) |
(4,023) |
(4,209) |
(522) |
(4,731) |
|||||||
|
Issuance of common shares |
2,351 |
– |
– |
– |
2,351 |
– |
2,351 |
|||||||
|
Share-based compensation |
– |
121 |
– |
– |
121 |
– |
121 |
|||||||
|
Forfeited options |
671 |
(671) |
– |
– |
– |
– |
– |
|||||||
|
Balance as of June 30, 2023 |
$ 248,798 |
$ 14,617 |
$ 1,097 |
$ (243,597) |
$ 20,915 |
$ 623 |
$ 21,538 |
|||||||
|
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
||||||||||||||
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||
|
Canadian Dollars in thousands |
||||
|
Six months ended June 30, |
||||
|
2024 |
2023 |
|||
|
Cash provided by operating activities: |
||||
|
Net income (loss) for the period |
$ (9,476) |
$ (4,572) |
||
|
Adjustments for non-cash items: |
||||
|
Fair value adjustment on sale of inventory |
25 |
617 |
||
|
Fair value adjustment on Warrants, investments and accounts receivable |
20 |
(3,304) |
||
|
Interest recorded in respect of the convertible debt |
115 |
– |
||
|
Depreciation of property, plant and equipment |
226 |
337 |
||
|
Amortization of intangible assets |
769 |
898 |
||
|
Depreciation of right-of-use assets |
196 |
352 |
||
|
Finance expenses, net |
1,792 |
2,683 |
||
|
Deferred tax liability, net |
(107) |
(220) |
||
|
Share-based payment |
120 |
121 |
||
|
Loss from deconsolidation of subsidiary |
2,764 |
– |
||
|
Net proceeds of convertible debt allocated to conversion option |
327 |
– |
||
|
6,247 |
1,484 |
|||
|
Changes in working capital: |
||||
|
Increase in trade receivables |
(5,821) |
(2,428) |
||
|
Increase in other accounts receivable and advances to suppliers |
(256) |
(2,572) |
||
|
Decrease in inventories, net of fair value adjustments |
3,424 |
1,484 |
||
|
Decrease (increase) in trade payables |
7,309 |
(5,078) |
||
|
Changes in employee benefit liabilities, net |
(47) |
(106) |
||
|
Increase in other accounts payable and accrued expenses |
(892) |
(992) |
||
|
3,717 |
(9,692) |
|||
|
Taxes paid |
(120) |
(432) |
||
|
Net cash provided (used) in operating activities |
368 |
(13,212) |
||
|
Cash flows from investing activities: |
||||
|
Purchase of property, plant and equipment |
(52) |
(553) |
||
|
Deconsolidation of subsidiary |
(346) |
– |
||
|
Net cash used in investing activities |
$ (398) |
$ (553) |
||
|
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
||||
|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
|||||
|
Canadian Dollars in thousands |
|||||
|
Six months ended June 30, |
|||||
|
2024 |
2023 |
||||
|
Cash flow from financing activities: |
|||||
|
Proceeds from issuance of share capital, net of issuance costs |
$ – |
$ 1,688 |
|||
|
Proceeds from issuance of warrants |
– |
6,585 |
|||
|
Repayment of lease liability |
(197) |
(345) |
|||
|
Interest paid – lease liability |
(25) |
(34) |
|||
|
Repayment of bank loan and credit facilities |
(2,392) |
(1,060) |
|||
|
Cash paid for interest |
(1,054) |
(124) |
|||
|
Proceeds from discounted checks |
4,311 |
3,967 |
|||
|
Net cash provided by financing activities |
643 |
10,677 |
|||
|
Effect of foreign exchange on cash and cash equivalents |
(1,726) |
1,960 |
|||
|
Decrease in cash and cash equivalents |
(1,113) |
(1,128) |
|||
|
Cash and cash equivalents at beginning of the period |
1,813 |
2,449 |
|||
|
Cash and cash equivalents at end of the period |
$ 700 |
$ 1,321 |
|||
|
Supplemental disclosure of non-cash activities: |
|||||
|
Right-of-use asset recognized with corresponding lease liability |
$ 40 |
$ 49 |
|||
|
Issuance of shares in payment of debt settlement to a non-independent director of the company |
$ – |
$ 1,061 |
|||
|
The accompanying notes are an integral part of the interim condensed consolidated financial statements. |
|||||
Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-reports-second-quarter-financial-results-302222219.html
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Indivior2 weeks agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
-
Cannabis5 days ago
One World Products Issues Shareholder Update Letter
-
Cannabis5 days agoIM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
